Journal of Chemotherapy

Papers
(The H4-Index of Journal of Chemotherapy is 10. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)
ArticleCitations
Successful treatment of persistent SARS-CoV-2 infection with nirmatrelvir/ritonavir plus sotrovimab in four immunocompromised patients24
The tumor microenvironment: shaping cancer progression and treatment response19
Prognostic implications of response to neoadjuvant chemotherapy in breast cancer subtypes16
Mechanisms underlying dose-limiting toxicities of conventional chemotherapeutic agents14
Piperacillin/Tazobactam is associated with a higher risk of acute kidney injury compared to cefepime and meropenem14
Clinical benefit of anti-PD-1/PD-L1 plus chemotherapy in first-line treatment for patients over the age of 65 or 75 with metastatic non-small cell lung cancer (NSCLC)12
Factors associated with immune-related thyroid dysfunction induced by PD-1/PD-L1 inhibitors in cancer patients: an observational study12
Effect of SARS-CoV-2 vaccination in a vulnerable COVID-19 cohort: a real-life experience in an Italian Hospital11
Real life experience of patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study11
Enzalutamide combination with Arsenic trioxide suppresses the progression of castration-resistant prostate cancer10
Class 1, 2 and 3 integrons in clinical Pseudomonas aeruginosa isolated from Tanta University Hospitals, Egypt10
Underutilisation of prophylactic G-CSF in breast cancer patients receiving adjuvant docetaxel/cyclophosphamide chemotherapy10
MiR-302a-3p reduces cisplatin resistance of esophageal squamous cell carcinoma cells by targeting EphA210
Comparative in vitro activities of eravacycline in combination with colistin, meropenem, or ceftazidime against various Achromobacter spp. strains isolated from patients with cystic fibrosis10
Clinical outcome and safety profile of metastatic pancreatic cancer patients treated with more than six cycles of nab-paclitaxel plus gemcitabine10
Improving therapeutic resistance: beginning with targeting the tumor microenvironment10
0.050044059753418